Cooper Companies (NYSE:COO) Price Target Lowered to $392.00 at Robert W. Baird

Cooper Companies (NYSE:COOGet Rating) had its price objective decreased by Robert W. Baird from $437.00 to $392.00 in a research note issued to investors on Thursday, The Fly reports.

Several other brokerages have also recently weighed in on COO. StockNews.com started coverage on shares of Cooper Companies in a research note on Thursday, March 31st. They issued a hold rating for the company. Piper Sandler lifted their price objective on shares of Cooper Companies from $490.00 to $500.00 in a research note on Friday, March 4th. Stephens lifted their price objective on shares of Cooper Companies from $430.00 to $500.00 and gave the stock an overweight rating in a research note on Monday, March 7th. Needham & Company LLC started coverage on shares of Cooper Companies in a research note on Friday, April 8th. They issued a hold rating for the company. Finally, Citigroup upgraded shares of Cooper Companies from a neutral rating to a buy rating and dropped their price objective for the stock from $460.00 to $405.00 in a research note on Tuesday, May 17th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of Buy and an average target price of $448.44.

Shares of COO opened at $352.17 on Thursday. The firm has a 50-day moving average of $378.40 and a 200-day moving average of $393.26. Cooper Companies has a one year low of $309.43 and a one year high of $463.59. The company has a market cap of $17.36 billion, a PE ratio of 18.68, a price-to-earnings-growth ratio of 2.29 and a beta of 0.90. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.02 and a quick ratio of 0.67.

Cooper Companies (NYSE:COOGet Rating) last announced its earnings results on Thursday, March 3rd. The medical device company reported $3.24 EPS for the quarter, topping the consensus estimate of $3.10 by $0.14. The business had revenue of $787.20 million during the quarter, compared to the consensus estimate of $739.30 million. Cooper Companies had a net margin of 31.00% and a return on equity of 9.89%. Cooper Companies’s revenue was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.17 EPS. Analysts expect that Cooper Companies will post 13.99 earnings per share for the current year.

In related news, SVP Agostino Ricupati sold 5,607 shares of Cooper Companies stock in a transaction that occurred on Friday, March 18th. The shares were sold at an average price of $421.51, for a total transaction of $2,363,406.57. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Gary S. Petersmeyer sold 300 shares of Cooper Companies stock in a transaction that occurred on Monday, April 11th. The shares were sold at an average price of $410.55, for a total transaction of $123,165.00. The disclosure for this sale can be found here. Insiders have sold a total of 19,646 shares of company stock worth $8,195,614 over the last ninety days. 1.70% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Cooper Companies by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 5,368,727 shares of the medical device company’s stock worth $2,241,927,000 after acquiring an additional 70,640 shares during the last quarter. BlackRock Inc. grew its holdings in Cooper Companies by 4.1% during the 4th quarter. BlackRock Inc. now owns 4,000,869 shares of the medical device company’s stock worth $1,676,126,000 after acquiring an additional 158,358 shares during the last quarter. State Street Corp grew its holdings in Cooper Companies by 0.5% during the 1st quarter. State Street Corp now owns 2,177,872 shares of the medical device company’s stock worth $909,458,000 after acquiring an additional 10,373 shares during the last quarter. Veritas Asset Management LLP grew its holdings in Cooper Companies by 12.0% during the 4th quarter. Veritas Asset Management LLP now owns 2,001,678 shares of the medical device company’s stock worth $838,583,000 after acquiring an additional 214,700 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in Cooper Companies by 10.8% during the 1st quarter. Invesco Ltd. now owns 1,620,188 shares of the medical device company’s stock worth $676,575,000 after acquiring an additional 157,305 shares during the last quarter. 98.38% of the stock is currently owned by hedge funds and other institutional investors.

About Cooper Companies (Get Rating)

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific.

Read More

The Fly logo

Analyst Recommendations for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.